Lercanidipine Hcl Aurobindo (Lercanidipine Hydrochloride)

Lercanidipine blocks L-type calcium channels in the smooth muscle of arteries. By preventing calcium entry, the drug reduces muscle contraction, leading to vasodilation. This widening of blood vessels decreases peripheral resistance and consequently lowers systemic blood pressure.

The appropriate dose of Lercanidipine is determined by the prescribing healthcare professional based on the patient’s condition, response to therapy, and any other medications being taken. Patients should follow the dosage instructions provided by their prescriber.

Safety of Lercanidipine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Lercanidipine is a dihydropyridine calcium channel blocker, offering once‑daily dosing and a favorable side‑effect profile compared with some older agents. Compared with ACE inhibitors or ARBs, it primarily causes vasodilation without affecting the renin‑angiotensin system, making it a useful alternative or add‑on therapy.

Lercanidipine tablets should be stored at ambient temperature, below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Lercanidipine is taken orally, usually once daily with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include severe hypotension, myocardial infarction, angioedema, and rare cases of hepatic dysfunction or life‑threatening arrhythmias. Patients should seek immediate medical attention if they experience symptoms such as fainting, chest pain, swelling of the face or throat, or unusual liver-related signs.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors without medical supervision.